This article is more than 5 years old. Information may no longer be current.
NLR predicted outcomes in patients with lung cancer, VTE
Click Here to Manage Email Alerts
Neutrophil-to-lymphocyte ratio at the time of venous thromboembolism diagnosis predicted how patients with lung cancer would respond to anticoagulation, according to study results.
Prior research has established that neutrophil-to-lymphocyte ratio (NLR) is a useful marker to predict outcomes in patients with cardiovascular disease, diabetes and other malignancies.
In the current study, researchers assessed whether NLR would predict response and survival in a cohort of patients with lung cancer who underwent anticoagulation for newly diagnosed VTE.
Researchers assessed the clinical characteristics, laboratory parameters and NLR in 114 patients.
Results showed that a high NLR was significantly associated with high hematocrit levels (P=.028), high levels of C-reactive protein (P=.002) and low levels of albumin (P=.001).
Patients in the high NLR group were more likely to have stage IV non–small cell lung cancer at the time of VTE diagnosis (74.6% vs. 55.6%; P=.055), central nervous system metastasis (25.8% vs. 5.8%; P=.004) and cancer progression at the time of VTE diagnosis (38.8 vs. 14.3%; P=.008).
Patients who demonstrated a poor response to anticoagulation were most likely to have NSCLC (P=.037), a high NLR (P=.004) and low albumin levels (P=.029).
Disclosure: See the study for a full list of the researchers’ relevant financial disclosures.
Click Here to Manage Email Alerts